1. Pink Sheet
  2. >>Biosimilars & Generics
  3. >>Biosimilars

Australia Says No To ‘Complex’ US-Style Suffixes For Biologicals

 
• By Vibha Sharma

Australia's Therapeutic Goods Administration wants to avoid the complexity and potential confusion associated with the introduction of a suffix-based system for naming biological medicines. The TGA has instead decided to supplement its existing naming convention for biologicals with a strengthened framework for reporting adverse events.

Magnifying glass focusing on Australia
Australia Plans To Strengthen Adverse Event Reporting For Biologicals • Source: Shutterstock

Australia's Therapeutic Goods Administration has given up the idea of adopting the US approach of requiring sponsors to add four-digit suffixes to the non-proprietary name of biological medicines to support their unique identification. The agency is concerned that the US approach may result in unnecessary regulatory burden for sponsors and could also cause confusion.

Following an extensive consultation with stakeholders, the TGA is not making any changes to its current naming convention for biological medicines for now and will continue with its...

More from Biosimilars

ICH Targets RWE, Rare Diseases, Biosimilars, ATMPs In New Guideline Push

 
• By Vibha Sharma

The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.

EU Biosimilar Filings, Opinions And Approvals

 
• By Neena Brizmohun

A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.

Pulling Together: Global Regulators Discuss Convergence On Biosimilars

 
• By Dave Wallace

While the biosimilars industry has welcomed individual pockets of progress around regulatory streamlining, it is essential that approaches from global authorities move forward together if they are to have a meaningful impact on biosimilar development. At Medicines for Europe’s annual biosimilars conference, regulators from around the world talked about how their thinking is converging.

Missing BsUFA Revenue Trigger Could Open US FDA Staff To Criminal Penalty

 
• By Derrick Gingery

Massive layoffs and the biosimilar user fee program’s historic flirtation with the non-user fee spending requirements raise concerns that the FDA could lose its ability to collect BsUFA revenue, which could mean a fine or jail time for agency staff.

More from Biosimilars & Generics

US FDA Guidance Roadblock: Writing Continues, But Publication Has Slowed Or Stopped

 
• By Derrick Gingery

Cuts to the FDA’s policy and legal personnel have prevented dozens of product-specific guidances for generic drug development from being published.

Viatris Agrees To $335m Opioid Settlement Ending US State, Local Government Cases

 
• By Dean Rudge

Viatris joined Hikma and Amneal, in signing agreements for cash settlements that resolve allegations its practices fueled the US’ deadly opioid epidemic.

US FDA Shows Support For Generic Drug User Fee Goals Amid Cutbacks

 
• By Michael McCaughan

The FDA struck an upbeat tone during its annual Generic Drugs Forum despite an unprecedented period of cutbacks and disruptions and reiterated a desire to continue meeting user fee goals.